Cargando…

Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy

The aim of this study was to determine the impact of ABCB1 polymorphism, BMI, age and drug co-administration on safety and efficiency of posaconazole (PCZ) oral suspension treatment in children with hematological diseases. Seventy children were included in the study. ABCB1 polymorphism in fifty-eigh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sienkiewicz-Oleszkiewicz, Beata, Urbańczyk, Kamila, Stachowiak, Mateusz, Rodziewicz, Anna, Zięba, Aleksander, Kałwak, Krzysztof, Wiela-Hojeńska, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825114/ https://www.ncbi.nlm.nih.gov/pubmed/31741622 http://dx.doi.org/10.1007/s12288-019-01134-5

Ejemplares similares

Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016)

Antifungal Drug-Drug Interactions with Commonly Used Pharmaceutics in European Pediatric Patients with Acute Lymphoblastic Leukemia
por: Sienkiewicz-Oleszkiewicz, Beata, et al.
Publicado: (2023)

Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
por: Sienkiewicz, Beata, et al.
Publicado: (2017)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report
por: Beata, Sienkiewicz, et al.
Publicado: (2017)

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Polypharmacotherapy in Psychiatry: Global Insights from a Rapid Online Survey of Psychiatrists
por: Ordak, Michal, et al.
Publicado: (2022)

Pseudoephedrine—Benefits and Risks
por: Głowacka, Krystyna, et al.
Publicado: (2021)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Nephrotoxicity of Herbal Products in Europe—A Review of an Underestimated Problem
por: Kiliś-Pstrusińska, Katarzyna, et al.
Publicado: (2021)

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study
por: Özkocaman, Vildan, et al.
Publicado: (2018)

Antibiotics and the Nervous System—Which Face of Antibiotic Therapy Is Real, Dr. Jekyll (Neurotoxicity) or Mr. Hyde (Neuroprotection)?
por: Hurkacz, Magdalena, et al.
Publicado: (2021)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

Over the Counter Pain Medications Used by Adults: A Need for Pharmacist Intervention
por: Karłowicz-Bodalska, Katarzyna, et al.
Publicado: (2023)

Therapeutic drug monitoring of amikacin in septic patients
por: Duszynska, Wieslawa, et al.
Publicado: (2013)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study
por: Li, Weiyang, et al.
Publicado: (2020)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2012)

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report
por: Mody, Mayur D., et al.
Publicado: (2017)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole
por: Szekalska, Marta, et al.
Publicado: (2019)

Odours count: human olfactory ecology appears to be helpful in the improvement of the sense of smell
por: Oleszkiewicz, Anna, et al.
Publicado: (2021)

Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study
por: Chen, Xiaochen, et al.
Publicado: (2021)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

Application of Novel Pharmacists’ Risk in Pharmacotherapy (PHARIPH) Scale for Identification of Factors Affecting the Safety of Hospital Pharmacotherapy—An Observational Pilot Study
por: Fedorowicz, Olga, et al.
Publicado: (2022)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage
por: Gedik, Habip, et al.
Publicado: (2014)

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
por: Maciaszek, Julian, et al.
Publicado: (2023)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Contrast Media Adverse Drug Reactions in Highly Polluted Environment
por: Sauer, Natalia, et al.
Publicado: (2022)

Effects of Non-Opioid Analgesics on the Cell Membrane of Skin and Gastrointestinal Cancers
por: Janicka, Natalia, et al.
Publicado: (2022)

Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans
por: Chen, Ying-Lien, et al.
Publicado: (2013)

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
por: Castanheira, Mariana, et al.
Publicado: (2020)

Mucoadhesive Alginate/Pectin Films Crosslinked by Calcium Carbonate as Carriers of a Model Antifungal Drug—Posaconazole
por: Szekalska, Marta, et al.
Publicado: (2023)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9rdin3997tdugdgqvop7vbn0nq